Charles Kumps, Chief Innovation & Development Officer at IBA, commented: “FLASH is a key research area that may dramatically improve the clinical relevance of Proton Therapy for patients around the world. As the industry leader, IBA has always collaborated with leading academic and industrial partners to bring innovation that continuously improves treatment outcomes to the forefront: The Universal Nozzle, Cone Beam CT and Proteus®ONE are amongst the developments that these partnerships have made possible.
Building upon this innovation process, IBA is now partnering with leading research institutions on FLASH Proton Therapy. This input is critical to further define the clinical impact of FLASH and to expand the performance and technical specifications of IBA’s proton therapy systems. As a result of these collaborations, we continue to lead the way in FLASH research.”
About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,400 people worldwide, IBA has installed systems across the world.
IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
Back to HCB News
